Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corp (NQ: TWST )

53.19 +0.36 (+0.68%)
Streaming Delayed Price Updated: 2:56 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Twist Bioscience Corp

< Previous 1 2 3 4 5 6 7 8 Next >
Twist Bioscience Highlights Synthetic Libraries and High Throughput Antibody Discovery Platform at PEGS Boston 2022
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches High Throughput Antibody Production Platform
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Become Voting Member of Storage Networking Industry Association
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Promotions and Changes to Executive Leadership Team
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2022 Second Quarter Financial Results on Thursday, May 5, 2022
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Signs Antibody Discovery Collaboration with MediSix Therapeutics to Develop T-cell Therapies
From Twist Bioscience Corporation
Via Business Wire
DNA Data Storage Alliance Welcomes 50th Member
From DNA Data Storage Alliance
Via Business Wire
Twist Bioscience and Ginkgo Bioworks Sign New Collaboration
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Synthetic RNA Positive Controls for SARS-CoV-2 Encapsulated in Imagene’s Stainless Steel Capsules
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Becomes Digital Preservation Coalition Supporter
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at Upcoming Virtual Conferences
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Pricing of an Upsized $250 Million Public Offering of Common Stock
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Proposed Public Offering of Common Stock
From Twist Bioscience Corporation
Via Business Wire
C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Reports First Quarter 2022 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2022 First Quarter Financial Results on Friday, February 4, 2022
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience’s Comprehensive DNA Synthesis Capabilities Expanded as Industry-Leading Enzymatic Synthesis Process Unveiled at Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Creates Custom Whole Exome Target Enrichment Panel for Canine Genomic Research
From Twist Bioscience Corporation
Via Business Wire
Revelar Biotherapeutics and Twist Bioscience Announce RBT-0813 Neutralizes SARS-CoV-2 Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) Variants
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches 96-Plex Library Prep Kit for Low Pass High Throughput Next-Generation Sequencing
From Twist Bioscience Corporation
Via Business Wire
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Circulating Tumor DNA Reference Controls for Development of Liquid Biopsy Assays
From Twist Bioscience Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.